Drugs / CART-38 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05442580 | May 2023 → Feb 2025 | acute myeloid leukemia, plasma cell myeloma | University of Pennsylvania | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART-38 cells | “This CAR T cell product will be referred to as "CART-38 cells".” NCT05442580 ↗ |
| Modality | Cell therapy | “lentivirally transduced T cells expressing anti-CD38 chimeric antigen receptors” NCT05442580 ↗ |
| Route | Intravenous | “3x10(6) CART-38 cells via intravenous infusion” NCT05442580 ↗ |
| Target | CD38 | “anti-CD38 chimeric antigen receptors” NCT05442580 ↗ |